Physician profile
Charnjit Singh
NPI 1285603571
$6,841.51
in general payments reported to CMS, 2019-2025
38 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $918 · 2020: $143 · 2021: $568 · 2022: $1,304 · 2023: $1,195 · 2024: $1,404 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849 · Education: $59.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.31 |
| Education | $59.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,868.05 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $645.86 | 2019-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $600.86 | 2021-2023 | |
| Janssen Biotech, INC. | $577.74 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $381.81 | 2021-2024 | Zeposia |
| Pfizer INC. | $281.26 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $243.87 | 2021-2024 | Linzess |
| Redhill Biopharma INC. | $206.54 | 2021-2024 | Talicia |
| Takeda Pharmaceuticals U.S.A., INC. | $166.59 | 2020-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $161.89 | 2024-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $158.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $143.63 | 2019-2024 | |
| Ardelyx, INC. | $120.68 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $117.35 | 2024-2025 | Zymfentra, Vegzelma |
| Genzyme Corporation | $114.03 | 2023-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $113.46 | 2024 | Apollo Esg System |
| Intercept Pharmaceuticals, INC. | $105.03 | 2019-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $101.45 | 2024-2025 | Voquezna |
| Allergan, INC. | $77.77 | 2019-2020 | |
| Organon LLC | $75.71 | 2023-2024 | Renflexis, Hadlima |
| Gilead Sciences, INC. | $71.41 | 2019-2021 | |
| Qol Medical, LLC | $59.95 | 2019-2024 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $54.43 | 2025 | Iqirvo, Bylvay |
| Aimmune Therapeutics, INC. | $53.64 | 2024 | |
| Micro-Tech Endoscopy USA, INC. | $47.56 | 2024-2025 | Lesionhunter, Lockado |
| Endo Pharmaceuticals INC. | $41.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.48 | 2023 | Cyltezo |
| Erbe USA INC | $30.00 | 2024 | Vio300d |
| Intra-Sana Laboratories | $27.00 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Horizon Therapeutics Plc | $25.06 | 2021-2022 | |
| Novo Nordisk INC | $23.69 | 2025 | Wegovy |
| Evoke Pharma, INC. | $19.89 | 2024 | |
| Capsovision, INC. | $17.21 | 2025 | Capsocam Plus |
| Braintree Laboratories, INC. | $15.94 | 2024 | Suflave |
| Janssen Pharmaceuticals, INC | $15.17 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.31 | 2022 | |
| Medtronic, INC. | $13.67 | 2023 | Gi Genius |
| Shionogi INC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charnjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.